Bonson K R, Murphy D L
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892-1264, USA.
Behav Brain Res. 1996;73(1-2):229-33. doi: 10.1016/0166-4328(96)00102-7.
This study sought to investigate possible interactions between antidepressant agents and lysergic acid diethylamide (LSD) in humans through the use of retrospective questionnaires. Ten subjects were identified who used LSD during chronic (3 weeks or longer) periods of antidepressant administration. These subjects were asked to describe the phenomenological effects of self-administered hallucinogens prior to and during antidepressant treatment; a structured, standardized questionnaire was used to evaluate LSD experiences. Chronic tricyclic antidepressant administration was associated with subjective increases in physical, hallucinatory and psychological responses to LSD. Similarly, subjects receiving lithium chronically also reported increases in their responses to LSD. In contrast, subjects who had been chronically taking an monoamine oxidase (MAO) inhibitor reported subjective decreases in the effects of LSD. This is similar to a previous report by our group of a decreased response to LSD in individuals who were chronically taking serotonin-selective antidepressants. These altered responses to LSD most likely involve differential changes in central serotonin and dopamine receptor systems and are consistent with other recent data suggesting that the clinical efficacy of different classes of antidepressants may not necessarily rely on a common mechanism of action in the brain.
本研究旨在通过使用回顾性问卷来调查抗抑郁药与麦角酸二乙酰胺(LSD)在人体中可能存在的相互作用。确定了10名在长期(3周或更长时间)服用抗抑郁药期间使用LSD的受试者。这些受试者被要求描述在抗抑郁治疗之前和期间自行服用致幻剂的现象学效应;使用结构化、标准化问卷来评估LSD体验。长期服用三环类抗抑郁药与对LSD的身体、幻觉和心理反应的主观增强有关。同样,长期服用锂盐的受试者也报告对LSD的反应增强。相比之下,长期服用单胺氧化酶(MAO)抑制剂的受试者报告LSD的效应主观降低。这与我们小组之前的一份报告类似,该报告指出长期服用血清素选择性抗抑郁药的个体对LSD的反应降低。这些对LSD的改变反应很可能涉及中枢血清素和多巴胺受体系统的差异变化,并且与最近的其他数据一致,这些数据表明不同类别的抗抑郁药的临床疗效不一定依赖于大脑中的共同作用机制。